Current practices in antibiotic prophylaxis for patients on complement inhibitors: a multicenter survey across ERN ERKnet centers
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background: Complement inhibitors such as eculizumab and ravulizumab are increasingly used to treat rare complement-mediated diseases. While effective, these therapies impair host defenses against encapsulated bacteria, leading to a heightened risk of invasive infections. Although vaccination is standard, the role and implementation of antibiotic prophylaxis remain inconsistent across clinical settings. Methods: A survey was conducted among European Reference Network for Rare Kidney Diseases (ERN ERKNet) centers to assess current practices regarding antibiotic prophylaxis in patients receiving complement-inhibition therapy. The survey addressed four clinical scenarios-pediatric vs. adult, transplant recipient vs. non-transplant-and explored three domains: indications for prophylaxis, choice of antibiotic, and duration. Results: Twenty-seven centers from 16 European countries participated. Systematic prophylaxis was widely endorsed, particularly for pediatric patients and transplant recipients. Penicillin-class antibiotics were preferred as first-line agents across all groups. In pediatric settings, phenoxymethylpenicillin and amoxicillin were most commonly used, whereas adult regimens included penicillin or fluoroquinolones for those with allergies. Most respondents recommended continuing prophylaxis throughout the duration of complement-inhibition therapy, regardless of vaccination status. The survey revealed areas of heterogeneity in practice, especially regarding allergy management and the duration of post-vaccination coverage. Conclusions: This ERKNet survey identifies prevailing practices and variation in antibiotic prophylaxis for patients receiving complement-inhibition therapy. Based on these findings, we propose consensus guidance to support harmonized, risk-adapted prophylaxis strategies across pediatric and adult populations. These guidance statements aim to address an important unmet need in infection prevention among complement-inhibited patients.
Source: Clinical Kidney Journal
DOI: 10.1093/ckj/sfag282
Authors: Savino Sciascia, Edoardo Terzolo, Roberta Fenoglio, Dario Roccatello, Stefanie Haeberle, Franz Schaefer, Nicole van de Kar, Marina Vivarelli, TMA ERN-ERKnet WG, Malgorzata Stanczyk, Stephanie Tellier, Marius Miglinas, Ana Teixeira, Rene Andersen, Huib De Jong, Josefina Santos Lascasas, Stathis Tsiakas, Adrian Lungu, Jerome Harambat, Caroline Duineveld, Laurent Mesnard, Luigi Cirillo, Enrique Morales, Giuseppe Grandaliano, Stéphane Decramer, Atif Awan, Ann Raes, Jakub Zieg, Mireya Carratala, Pedro Arango Sancho, Thomas Simon, Enrique Morales, Ann Raes, Carmen De Lucas Collantes, Nathalie Godefroid, Enrico Vidal, Alena Parikova, Johann Morelle, Cavero Teresa, Miquel Blasco, Evelien Snauwaert, Adrian Lungu, Alvaro Madrid, Martin Konrad
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,335
OpenAlex ID: W7203868713
FWCI:
Cites:
Cited by:
Related to: